-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the arrangements issued by the three departments of Guangdong Province on the implementation of the fifth batch of national-organized drug centralized procurement and use, the first-year procurement cycle will implement the results of the fifth batch of centralized procurement and supporting policies from 0:00 on October 9, 2021
.
This also means that starting from midnight today, public medical institutions in Guangdong will officially launch 61 centralized medicines with an average decrease of 55%, benefiting the majority of patients
.
The results of the fifth batch of national centralized procurement were announced on June 28 this year.
A total of 61 drugs were planned to be successfully purchased, involving 148 companies and 251 products
.
This round of centralized procurement involves drugs for common diseases such as hypertension, coronary heart disease, diabetes, gastrointestinal diseases, chronic diseases, and drugs for major diseases such as lung cancer, breast cancer, and colorectal cancer.
More than half of them are injections
.
It is understood that, based on the agreed purchases in the first year, the Guangdong province’s market sales were about 2.
489 billion yuan before the price cut, and about 507 million yuan after the price cut
.
In this collection, 16 varieties dropped by more than 90%.
Among them, Jiangsu Hausen's gemcitabine hydrochloride (1g) for injection and other products dropped by more than 97%
.
The price cuts of these medicines will help greatly reduce the burden of patients' drug expenses
.
It is worth mentioning that in addition to the sharp price cuts of the selected products, Guangdong has also linked the prices of non-selected drugs with the same generic names.
For example, more than 10 drugs such as fasudil hydrochloride injection have also dropped significantly, with an average drop of 70%
.
In addition, the province has also implemented supporting measures such as medical insurance payment standards to promote hospitals to give priority to the use of selected drugs with reliable quality and reasonable prices, and to guide and standardize diagnosis and treatment
.
It is reported that in the next step, Guangdong will accelerate the pace of procurement by the inter-provincial alliance, and will launch a batch of selected drugs with a larger scale, more variety and wider coverage before the end of the year, so that the masses can enjoy better quality and affordable medical services, and make drugs Centralized procurement reform dividends are further released
.
Up to now, in addition to Guangdong Province, Xinjiang, Tianjin, Henan, Tibet, Hebei, and Chongqing have also implemented the fifth batch of national procurement results.
In addition, Yunnan, Hainan, Hubei, Guangxi, Shandong, Gansu, Guizhou, Jiangxi, Shaanxi, Liaoning , Shanxi, Fujian, Zhejiang, Heilongjiang and other places have also clarified the implementation time of the fifth round of national procurement, mostly in mid-to-late October
.
According to the previous news from the National Medical Insurance Bureau, the fifth batch of national procurement will be launched nationwide in October.
The industry expects that by November, the remaining provinces will enter the implementation stage of the fifth batch of national procurement
.
Relevant information shows that since the establishment of the National Medical Insurance Bureau, it has carried out 5 batches of centralized drug purchases, covering 218 varieties, and involving a market capacity of 220 billion yuan
.
In accordance with the requirements of the normalized and institutionalized centralized drug procurement work, the scope of centralized drug procurement organized by the state will continue to expand, and the clinical drug demand will be oriented to ensure the quality and supply of drugs, and improve the benefits and sense of gain of the people
.
It should be noted that with the implementation of the fifth batch of national sourcing, the price reduction and withdrawal of unselected products and products that have not passed the consistency evaluation have also begun
.
In addition to the aforementioned Guangdong Province’s price linkage for non-selected drugs of the same generic name, Henan Province also recently issued a notice on the evaluation results of the fifth batch of national centralized procurement of non-selected drugs.
The notification shows that 457 drugs will face Withdraw the net
.
Overall, the price reduction of medicines has become a major trend
.
.
This also means that starting from midnight today, public medical institutions in Guangdong will officially launch 61 centralized medicines with an average decrease of 55%, benefiting the majority of patients
.
The results of the fifth batch of national centralized procurement were announced on June 28 this year.
A total of 61 drugs were planned to be successfully purchased, involving 148 companies and 251 products
.
This round of centralized procurement involves drugs for common diseases such as hypertension, coronary heart disease, diabetes, gastrointestinal diseases, chronic diseases, and drugs for major diseases such as lung cancer, breast cancer, and colorectal cancer.
More than half of them are injections
.
It is understood that, based on the agreed purchases in the first year, the Guangdong province’s market sales were about 2.
489 billion yuan before the price cut, and about 507 million yuan after the price cut
.
In this collection, 16 varieties dropped by more than 90%.
Among them, Jiangsu Hausen's gemcitabine hydrochloride (1g) for injection and other products dropped by more than 97%
.
The price cuts of these medicines will help greatly reduce the burden of patients' drug expenses
.
It is worth mentioning that in addition to the sharp price cuts of the selected products, Guangdong has also linked the prices of non-selected drugs with the same generic names.
For example, more than 10 drugs such as fasudil hydrochloride injection have also dropped significantly, with an average drop of 70%
.
In addition, the province has also implemented supporting measures such as medical insurance payment standards to promote hospitals to give priority to the use of selected drugs with reliable quality and reasonable prices, and to guide and standardize diagnosis and treatment
.
It is reported that in the next step, Guangdong will accelerate the pace of procurement by the inter-provincial alliance, and will launch a batch of selected drugs with a larger scale, more variety and wider coverage before the end of the year, so that the masses can enjoy better quality and affordable medical services, and make drugs Centralized procurement reform dividends are further released
.
Up to now, in addition to Guangdong Province, Xinjiang, Tianjin, Henan, Tibet, Hebei, and Chongqing have also implemented the fifth batch of national procurement results.
In addition, Yunnan, Hainan, Hubei, Guangxi, Shandong, Gansu, Guizhou, Jiangxi, Shaanxi, Liaoning , Shanxi, Fujian, Zhejiang, Heilongjiang and other places have also clarified the implementation time of the fifth round of national procurement, mostly in mid-to-late October
.
According to the previous news from the National Medical Insurance Bureau, the fifth batch of national procurement will be launched nationwide in October.
The industry expects that by November, the remaining provinces will enter the implementation stage of the fifth batch of national procurement
.
Relevant information shows that since the establishment of the National Medical Insurance Bureau, it has carried out 5 batches of centralized drug purchases, covering 218 varieties, and involving a market capacity of 220 billion yuan
.
In accordance with the requirements of the normalized and institutionalized centralized drug procurement work, the scope of centralized drug procurement organized by the state will continue to expand, and the clinical drug demand will be oriented to ensure the quality and supply of drugs, and improve the benefits and sense of gain of the people
.
It should be noted that with the implementation of the fifth batch of national sourcing, the price reduction and withdrawal of unselected products and products that have not passed the consistency evaluation have also begun
.
In addition to the aforementioned Guangdong Province’s price linkage for non-selected drugs of the same generic name, Henan Province also recently issued a notice on the evaluation results of the fifth batch of national centralized procurement of non-selected drugs.
The notification shows that 457 drugs will face Withdraw the net
.
Overall, the price reduction of medicines has become a major trend
.
